Detection of PD-1 and CD28 Expression in Lymphocytes by Flow Cytometry.
1/5 보강
[BACKGROUND] Cancer immunotherapy research, immune microenvironment exploration, and biomarker discovery are key application areas of immune checkpoint analysis.
APA
Chen S, Wu X, et al. (2026). Detection of PD-1 and CD28 Expression in Lymphocytes by Flow Cytometry.. The journal of applied laboratory medicine, 11(2), 330-344. https://doi.org/10.1093/jalm/jfaf202
MLA
Chen S, et al.. "Detection of PD-1 and CD28 Expression in Lymphocytes by Flow Cytometry.." The journal of applied laboratory medicine, vol. 11, no. 2, 2026, pp. 330-344.
PMID
41543012
Abstract
[BACKGROUND] Cancer immunotherapy research, immune microenvironment exploration, and biomarker discovery are key application areas of immune checkpoint analysis. PD-1 and CD28 are crucial receptors expressed on the surface of T cells, playing vital roles in regulating T cell activation and immune response. Accurate detection of these immune checkpoints, such as PD-1 and CD28 on lymphocytes, is essential for understanding immune responses, particularly in clinical contexts such as cancer immunotherapy. Flow cytometry offers a precise approach to detect these markers in whole blood samples.
[METHODS] This study developed and optimized a flow cytometry-based detection method utilizing the CYTEK NL-CLC flow cytometer to quantitatively assess the expression of PD-1 and CD28 on lymphocytes. A detailed protocol was established and validated, focusing on key performance parameters.
[RESULTS] Our method showed high sensitivity and specificity, providing a powerful tool for immune monitoring and treatment decision-making. Validation results, including precision, dilution linearity, fluorescence stability, reference interval, and accuracy, all met acceptable criteria and have been reviewed and approved for clinical testing.
[CONCLUSIONS] The CYTEK NL-CLC flow cytometer is positioned as a reliable and effective platform for immune checkpoint analysis in both clinical and research settings, supporting its integration into cancer immunotherapy workflows and personalized medicine strategies.
[METHODS] This study developed and optimized a flow cytometry-based detection method utilizing the CYTEK NL-CLC flow cytometer to quantitatively assess the expression of PD-1 and CD28 on lymphocytes. A detailed protocol was established and validated, focusing on key performance parameters.
[RESULTS] Our method showed high sensitivity and specificity, providing a powerful tool for immune monitoring and treatment decision-making. Validation results, including precision, dilution linearity, fluorescence stability, reference interval, and accuracy, all met acceptable criteria and have been reviewed and approved for clinical testing.
[CONCLUSIONS] The CYTEK NL-CLC flow cytometer is positioned as a reliable and effective platform for immune checkpoint analysis in both clinical and research settings, supporting its integration into cancer immunotherapy workflows and personalized medicine strategies.
MeSH Terms
Flow Cytometry; Humans; CD28 Antigens; Programmed Cell Death 1 Receptor; Neoplasms; Immunotherapy; Reproducibility of Results; Sensitivity and Specificity; Lymphocytes
같은 제1저자의 인용 많은 논문 (5)
- [Tc]MIBI SPECT/CT for Identifying Dystonic Muscles in Patients with Primary Cervical Dystonia.
- Polyp image segmentation based on parallel dilated convolution and dual attention mechanisms.
- Peripheral blood biomarkers for predicting response to PD-1/PD-L1 inhibitors.
- Targeting KIF20A blocks lactylation modification to suppress immune escape in hepatocellular carcinoma.
- Noninvasive Profiling for PD-L1 and CTNNB1 Status in Hepatocellular Carcinoma.